Treatment of alzheimer's disease

Neurologist

Volumn 3, Issue 6, 1997, Pages 333-343

  Doody, Rachelle Smith ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Behavior; Cognition; Pharmacotherapy

Indexed keywords

EID: 0342884463     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199711000-00002     Document Type: Article

References (5)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadhn EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
2. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J Neurochem 1995;64:749-60.
3. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-1024.
4. Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. The Tacrine Collaborative Study Group: A double-blind, placebo-controlled multi-center study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
5. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.